One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial (Q38379744)

From Wikidata

Jump to navigation Jump to search

scientific article published on 08 March 2017

Language	Label	Description	Also known as
English	One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial	scientific article published on 08 March 2017

Statements

scholarly article

1 reference

Europe PubMed Central

2 September 2017

One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial (English)

1 reference

Europe PubMed Central

2 September 2017

Philippe Gabriel Steg

12

object named as

Philippe Gabriel Steg

0 references

1

object named as

Enrico Fabris

1 reference

Europe PubMed Central

2 September 2017

author name string

Sinem Kilic

2

1 reference

Europe PubMed Central

2 September 2017

Arnoud W J Van't Hof

3

1 reference

Europe PubMed Central

2 September 2017

Jurrien Ten Berg

4

1 reference

Europe PubMed Central

2 September 2017

Ana Ayesta

5

1 reference

Europe PubMed Central

2 September 2017

Uwe Zeymer

6

1 reference

Europe PubMed Central

2 September 2017

Martial Hamon

7

1 reference

Europe PubMed Central

2 September 2017

Louis Soulat

8

1 reference

Europe PubMed Central

2 September 2017

Debra Bernstein

9

1 reference

Europe PubMed Central

2 September 2017

Prodromos Anthopoulos

10

1 reference

Europe PubMed Central

2 September 2017

Efthymios N Deliargyris

11

1 reference

Europe PubMed Central

2 September 2017

publication date

8 March 2017

1 reference

Europe PubMed Central

2 September 2017

JAMA cardiology

1 reference

Europe PubMed Central

2 September 2017

2

1 reference

Europe PubMed Central

2 September 2017

791-796

1 reference

Europe PubMed Central

2 September 2017

7

1 reference

Europe PubMed Central

2 September 2017

Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction: A Patient-Level Analysis of 2 Randomized Trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543319

1 October 2018

Frequency and prognostic significance of access site and non-access site bleeding and impact of choice of antithrombin therapy in patients undergoing primary percutaneous coronary intervention. The EUROMAX trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543319

1 October 2018

An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543319

1 October 2018

Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543319

1 October 2018

Impact of arterial access site on outcomes after primary percutaneous coronary intervention: prespecified subgroup analysis from the EUROMAX trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543319

1 October 2018

Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543319

1 October 2018

Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543319

1 October 2018

Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543319

1 October 2018

Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543319

1 October 2018

Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543319

1 October 2018

Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the [...]

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543319

1 October 2018

Design and methods of European Ambulance Acute Coronary Syndrome Angiography Trial (EUROMAX): an international randomized open-label ambulance trial of bivalirudin versus standard-of-care anticoagulation in patients with acute ST-segment-elevation m

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543319

1 October 2018

Bivalirudin started during emergency transport for primary PCI.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5543319

1 October 2018

Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/28273285

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urge

1 reference

https://pubmed.ncbi.nlm.nih.gov/28273285

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1001/JAMACARDIO.2016.5975

1 reference

Europe PubMed Central

2 September 2017

0 references

1 reference

Europe PubMed Central

2 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38379744&oldid=1757033173"